India moves closer to rolling out 'drugs for all' plan (Update)
July 6, 2012 by Penny MacRae in Medications
India is moving ahead with ambitious plans to spend nearly $5 billion to supply free drugs to patients -- bringing the nation closer to universal health coverage, officials said on Friday.
The "game-changing" scheme, in the words of one top Indian health ministry official, is part of the government's latest five-year spending programme (2012-17) and is expected to start in October.
The centre-left Congress government will pay 200 billion rupees or $3.61 billion while India's 29 states will be asked to kick in 66 billion rupees over the next five years to the scheme, a government statement said.
This initiative "would be a giant step in vastly expanding the access to medicines" in the country of 1.2 billion people, Ministry of Health joint secretary Arun Panda said.
The plan is set for formal approval next month but the drug scheme has already received its first chunk of 10 billion rupees from India's Planning Commission for 2012-13.
Prime Minister Manmohan Singh, a champion of the so-called "free-medicines-for-all" scheme", has also asked the health ministry to set up a central procurement agency to obtain the drugs in bulk.
"This starts us on the road to universal health care," K. Srinath Reddy, head of the Public Health Foundation of India, told AFP.
"It won't happen overnight -- it may be 10 or 15 years but we're on our way," said Reddy, who chaired a high-level government panel that laid out a roadmap for universal coverage.
The drugs plan could give a filip to the embattled Congress government, reeling from a string of corruption scandals and a sharply slowing economy, ahead of the general elections set for 2014.
Gainers will also be India's booming generic drug companies that include giants Ranbaxy, Dr Reddy's and Cipla.
The scheme will offer cheaper generic versions of branded drugs -- shutting out international pharmaceutical giants -- but the firms have normally looked to the burgeoning class of more affluent Indians to buy their medicines.
"Globally, governments traditionally get their drugs from generic sources so it's no surprise India is not turning to branded drugs," said an analyst at an Indian brokerage who could not be named due to his company's policy.
The 348 drugs to be provided include anesthetics, anti-AIDS, anti-psychotic, steroid, anti-ulcer, cholesterol-busting and cancer medicines. Some five percent of funds are being set aside to buy drugs off the essential list.
The government is seeking to "provide affordable healthcare to the poor and vulnerable," additional health secretary L.C. Goyal said, adding India aimed to launch "the game-changing programme from October."
Some 78 percent of spending on health comes from Indians' own pockets -- one of the highest rates globally. Also, some 72 percent of health spending goes on drugs and not treatment, said Public Health Foundation's Reddy.
The health ministry hopes by 2017, some 52 percent of Indians or some 600 million people will have access to the drug scheme.
"Universal health care is not possible without essential drugs and we thought this is one of the early and easily implementable steps," said Reddy.
"It's a very welcome commitment by the government," Leena Menghaney, a lawyer with humanitarian group Medecins sans Frontieres (Doctors Without Borders) told AFP.
"But supply management will be key to ensure the drugs do not end up in the private market," she said, as is often the case with subsidised goods in India.
Free medicines cannot alleviate the country's overburdened public health care system in which many hospitals lack up-to-date equipment and doctors. Wealthier Indians routinely opt for India's better resourced private hospitals.
But the government estimates 40 million Indians are forced into poverty annually because of treatment costs. Others are forced to seek loans or sell assets.
"When my brother got ill and was in hospital for weeks, we sold some land," said Raju Choudhary, a junior executive. "Anything like this could help people in such a situation."
(c) 2012 AFP
-
Indian drug giant Cipla slashes cancer drug prices
May 04, 2012 |
not rated yet |
0
-
India firm shakes up cancer drug market with price cuts
Jun 17, 2012 |
not rated yet |
0
-
Bayer challenges India cancer drug ruling
May 06, 2012 |
not rated yet |
0
-
India probes charges of violations by drugs regulator
May 10, 2012 |
not rated yet |
0
-
Indian expert panel to probe drugs regulator
May 11, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
14 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
39 minutes ago |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
1 hour ago |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Controlling mood through the motions of mitochondria
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
Future doctors unaware of their obesity bias
Two out of five medical students have an unconscious bias against obese people, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published online ahead of print in the Journal of ...
WHO: Scientific red tape mars efforts vs. virus
International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...
Research identifies a way to make cancer cells more responsive to chemotherapy
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
Mayo Clinic genomic analysis lends insight to prostate cancer
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
Shortage of key drug hampering U.S. efforts to control TB, report says
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...